Ocular Therapeutix (OCUL) EBIT Margin (2014 - 2026)
Ocular Therapeutix (OCUL) recorded quarterly EBIT Margin of 865.46% in Q1 2026, down 64.38% quarter-over-quarter from 526.49% in Q4 2025, and down 26799.0% on a YoY basis from N/an in Q1 2025.
Ocular Therapeutix (OCUL) EBIT Margin (2014 - 2026) Analysis & Trends
Ocular Therapeutix's EBIT Margin history runs 13 years deep, the most recent figure standing at 865.46% for Q1 2026.
- In Q1 2026, EBIT Margin fell 26799.0% year-over-year to 865.46%; the TTM figure through Mar 2026 stood at 575.42% (down 23327.0% YoY), while the FY2025 annual figure was 519.75%, down 25018.0% from the prior year.
- EBIT Margin was 865.46% for Q1 2026 at Ocular Therapeutix, down from 526.49% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 127.41% in Q3 2023 to a low of 865.46% in Q1 2026.
- Historically, EBIT Margin has averaged 307.05% across 5 years, with a median of 214.0% in 2024.
- The sharpest annual moves came in 2022 and 2025: EBIT Margin jumped 14028 bps in 2022, then sank 38346 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 137.56% in 2022, then grew by 2 bps to 135.46% in 2023, then tumbled by 119 bps to 296.08% in 2024, then tumbled by 78 bps to 526.49% in 2025, then tumbled by 64 bps to 865.46% in 2026.
- The last three EBIT Margin figures came in at 865.46% (Q1 2026), 526.49% (Q4 2025), and 472.35% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn | -865.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -865.46% |
| Dec 31, 2025 | -526.49% |
| Sep 30, 2025 | -472.35% |
| Jun 30, 2025 | -502.57% |
| Mar 31, 2025 | -597.47% |
| Dec 31, 2024 | -296.08% |
| Sep 30, 2024 | -298.20% |
| Jun 30, 2024 | -265.13% |
| Mar 31, 2024 | -214.00% |
| Dec 31, 2023 | -135.46% |
| Sep 30, 2023 | -127.41% |
| Jun 30, 2023 | -135.45% |
| Mar 31, 2023 | -168.60% |
| Dec 31, 2022 | -137.56% |
| Sep 30, 2022 | -180.06% |
| Jun 30, 2022 | -162.37% |
| Mar 31, 2022 | -135.23% |
| Dec 31, 2021 | -146.64% |
| Sep 30, 2021 | -160.69% |
| Jun 30, 2021 | -172.65% |